Skip to main content

Table 2 Baseline and follow-up clinical characteristics of the study cohort

From: The association between variants in PLA2R and HLA-DQA1 and renal outcomes in patients with primary membranous nephropathy in Western China

Characteristic

Patients with PMN (n = 186)

Baseline

 

 Age at biopsy (years)

49.1 ± 13.4

 Male (n, %)

102 (54.8)

 SCr (μmol/L)

68.9 ± 22.5

 eGFR (ml/min/1.73 m2)

100.8 ± 20.7

 Urea (mmol/L)

5.6 ± 2.2

 Alb (g/L)

28.4 ± 19.1

 UA (μmol/L)

362.0 ± 95.5

 24 h-u-pro (g/d)

4.17 (2.31,7.34)

 SBP (mmHg)

128.4 ± 15.2

 DBP (mmHg)

78.5 ± 11.0

 Hypertension (n, %)

47 (25.3)

Follow-up

 

 SCr (μmol/L)

92.4 ± 89.1

 eGFR (ml/min/1.73 m2)

90.6 ± 29.9

 Urea (mmol/L)

6.6 ± 3.2

 Alb (g/L)

36.4 ± 8.5

 UA (μmol/L)

373.3.0 ± 106.6

 24 h-u-pro (g/d)

0.86 (0.15,2.65)

 Follow-up time (month)

18.6 (6.7,45.5)

 Endpoint event (n,%)

41 (22.0)

 Therapy

 

  Corticosteroid monotherapy (n,%)

29 (15.6)

  Immunosuppression (n,%)

112 (60.2)

  Non- Immunosuppression (n,%)

45 (24.2)

 Treatment effect

 

  Corticosteroid monotherapy

 

    CR/PR/non-SR (n,%)

12/6/11 (41.4, 20.7, 37.9)

  Immunosuppression

 

    CR/PR/non-SR (n,%)

37/21/54 (33.0, 18.8, 48.2)

  Non- Immunosuppression

 

    CR/PR/non-SR (n,%)

14/13/18 (31.1, 28.9, 40.0)

  1. The Endpoint event was defined as a combination of ESRD, a 30% reduction of eGFR from baseline and double times increasing of creatinine